The pharmacy transfer market is going through a pivotal period. On one hand, valuations have fallen by 25 to 30% over 10 years. On the other, new pharmaceutical services are opening up unprecedented revenue prospects. For candidates seeking to take over, it's a window of opportunity.
The market state in 2026
France has approximately 20,500 pharmacies, compared to 23,000 fifteen years ago. Closures are mainly affecting small rural pharmacies and city-center pharmacies competing with parapharmacies and e-commerce.
However, in parallel, pharmacies that adapt are thriving. The average turnover of a French pharmacy is 1.8 million euros, with an upward trend thanks to new services.
Valuation: how it's calculated
Historically, a pharmacy was valued at 80-100% of turnover excluding VAT. In 2026, multiples have fallen:
| Pharmacy profile | Multiple of turnover excluding VAT |
|---|---|
| Rural pharmacy (turnover < €1M) | 50-65% |
| Neighborhood pharmacy (turnover €1-2M) | 60-75% |
| Dynamic city-center pharmacy (turnover €2-4M) | 70-85% |
| High-volume pharmacy (turnover > €4M) | 75-90% |
Another indicator is EBITDA (earnings before interest, taxes, depreciation and amortization): pharmacies are sold between 5 and 8 times EBITDA depending on their attractiveness.
Factors that increase valuation:
- Location in an under-equipped area (captive clientele)
- Automated systems and modernized back-office
- Home care and parapharmacy services developed
- Favorable commercial lease (long duration, reasonable rent)
- Stable and competent team
Factors that decrease it:
- Dependence on a single prescriber (nursing home, single doctor)
- Outdated or poorly located premises
- Staff turnover
- Seller's debt
Financing
The good news: pharmacies are considered safe assets by banks. The default rate is among the lowest of all sectors (less than 0.5%).
Typical financing structure:
| Source | Share of financing |
|---|---|
| Personal contribution | 20-30% |
| Bank loan (7-12 years) | 50-60% |
| Seller credit (seller's loan) | 10-20% |
| Honor loan / BPI | 0-10% |
Banks specializing in pharmacies (Interfimo, subsidiaries of major banks) offer optimized terms. The arrangement generally goes through an SEL (Liberal Practice Company) that carries the loan.
Key point: annual loan repayment should not exceed 70% of EBITDA. Beyond that, cash flow will be too tight to absorb unexpected issues.
New services: the pharmacy of 2030
New services paid for by Health Insurance are a major growth driver:
Vaccination — flu, COVID, but also HPV, shingles, meningococcal. Revenue per act: €7.50 to €9.60. An active pharmacy can perform 300 to 500 vaccinations per year.
Diagnostic tests — rapid tests for sore throat, flu, COVID, urinary tract infection. The pharmacist performs the test and can dispense treatment directly (cooperation protocol). Revenue: €6 to €15 per test.
Medication reviews — support for patients taking multiple medications. €60 per review, renewable. A dozen per month generates €7,200 in additional annual revenue.
Pharmaceutical consultations — asthma, anticoagulants, cancer. Flat annual remuneration per followed patient.
Pharmaceutical telehealth — since 2024, pharmacists can conduct pharmaceutical consultations remotely. Emerging market with strong potential in rural areas.
Rural pharmacy: a special case
Rural pharmacies benefit from a dual advantage:
- The contract for support in under-equipped areas — the regional health authority can finance part of the investment
- ZRR benefits — tax exemption on profits for 5 years, applicable to SELs
A pharmacist taking over a rural pharmacy for €400,000 (50% of €800,000 turnover) with ZRR exemptions saves €15,000 to €25,000 in taxes over the first 5 years. Combined with a lower acquisition price and loyal clientele, profitability can be achieved faster than in the city.
The most common buying mistakes
Buying the pharmacy of your dreams without verifying reality — analyze the last 3 financial statements, turnover breakdown (prescriptions vs. parapharmacy vs. home care), trend (up or down), and especially adjusted EBITDA (adding the owner's actual compensation).
Neglecting the team — a pharmacy's success depends on its team. Meet the technicians before buying. High turnover is a red flag.
Underestimating work required — accessibility standards compliance, automated system modernization, privacy space redesign for new services... Post-takeover work often costs €30,000 to €80,000.
Pharmacy is a healthcare business. Successful takeover candidates are those who master both dimensions: care AND business.